In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline PLC

www.gsk.com

Latest From GlaxoSmithKline PLC

Less Success 'Expected' In 'OTC Setting' Trial For GSK's NRT, Expert Tells NDAC

While lower than  results in GSK standard efficacy trial, 'real world' success still is clinically significant, firm's experts tell FDA advisory committee after agency officials asked the panel to consider whether the results translate to clinically meaningful benefit for GSK's proposed mouth spray NRT.

United States Health

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.

China Policy & Regulation

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

Cancer Research & Development

In Vivo’s Quick Guide To Gene Therapy

Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.

Gene Therapy Innovation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register